CRBP

Corbus Pharmaceuticals Holdings, Inc.

Price Chart

Latest Quote

$8.26

+0.21 (+2.61%)

Current Price

Previous Close	$8.05
Open	$8.26
Day High	$8.47
Day Low	$8.02
Volume	297,759

Fetched: 2026-06-20T15:48:01

Stock Information

Shares Outstanding	18.53M
Total Debt	$1.21M
Cash Equivalents	$138.22M
Net Income	$-84.53M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$153.04M
EPS (TTM)	$-5.75
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$16.03M
Income	$-84.53M
Book/sh	$7.12
Cash/sh	$7.46
Employees	36

Financial Ratios

Quick Ratio	7.70
Current Ratio	7.92
Debt/Eq	0.95

Returns & Margins

ROA	-39.49%
ROE	-66.70%

Ownership

Insider Ownership	1.08%
Institutional Ownership	72.11%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.63
P/B	1.16

Analyst Data

Recommendation	strong_buy
Target Price	$36.30

Technical Indicators

SMA20	$8.19
SMA50	$9.54
SMA200	$10.23
RSI	55.49
ATR	0.4949

Shares Float	14.32M
Short Float	9.51%
Short Ratio	2.41
Volatility	2.59
Rel Volume	0.39

Performance History

Week	+6.17%
Month	-9.73%
Quarter	-7.61%
6 Months	-4.62%
YTD	+4.96%
Year	-0.24%
3 Years	-4.51%
5 Years	-87.37%
10 Years	-90.76%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$8.26	297,800
2026-06-17	$8.05	279,000
2026-06-16	$7.88	482,900
2026-06-15	$8.32	335,400
2026-06-12	$8.19	574,600
2026-06-11	$7.78	359,200
2026-06-10	$7.70	267,800
2026-06-09	$7.70	293,700
2026-06-08	$7.56	219,400
2026-06-05	$7.56	327,200
2026-06-04	$8.01	829,800
2026-06-03	$7.38	526,200
2026-06-02	$7.54	851,200
2026-06-01	$7.75	599,300
2026-05-29	$7.91	1,056,000
2026-05-28	$7.64	914,000
2026-05-27	$7.82	2,076,300
2026-05-26	$7.91	3,749,500
2026-05-22	$11.35	556,300
2026-05-21	$11.51	652,100
2026-05-20	$9.73	289,200
2026-05-19	$9.15	324,300

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

📰 Latest News

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

MarketBeat • 2026-06-09T09:02:11Z

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

MarketBeat • 2026-06-01T14:04:00Z

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

MarketBeat • 2026-05-22T07:04:54Z

Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls

The Fly • 2026-04-29T13:42:54Z

Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value

Insider Monkey • 2026-04-17T13:58:19Z

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

Zacks • 2026-03-11T13:55:02Z

Corbus Pharmaceuticals: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-09T11:48:55Z

Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead

MarketBeat • 2026-02-26T08:08:03Z

While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership

Simply Wall St. • 2025-12-27T13:44:02Z

Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss

MT Newswires • 2025-12-11T13:19:29Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$0	$1,872,000	$3,858,000	-
Total Expenses	$85,310,000	$48,721,000	$45,078,000	$34,835,445
Other Income Expense	$1,243,000	$4,073,000	$2,696,000	$-5,379,367
Other Non Operating Income Expenses	$1,243,000	$4,073,000	$2,696,000	$-48,773
Net Non Operating Interest Income Expense	$5,530,000	$4,439,000	$-2,222,000	$-2,132,091
Interest Expense Non Operating	$0	$1,872,000	$3,858,000	-
Operating Expense	$85,310,000	$48,721,000	$45,078,000	$34,835,445
General And Administrative Expense	$15,215,000	$16,499,000	$13,910,000	$18,698,619
Total Other Finance Cost	-	-	$2,923,974	$2,132,091
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Net Interest Income	$5,530,000	$4,439,000	$-2,222,000	$-2,132,091
Interest Income	$5,530,000	$6,311,000	$1,636,000	-
Normalized Income	$-78,537,000	$-40,209,000	$-44,604,000	$-37,016,309
Net Income From Continuing And Discontinued Operation	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Total Operating Income As Reported	$-85,310,000	$-48,721,000	$-45,078,000	$-39,835,445
Net Income Common Stockholders	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Net Income	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Net Income Including Noncontrolling Interests	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Net Income Continuous Operations	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Pretax Income	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Interest Income Non Operating	$5,530,000	$6,311,000	$1,636,000	-
Operating Income	$-85,310,000	$-48,721,000	$-45,078,000	$-34,835,445
Special Income Charges	-	-	$0	$-5,000,000
Per Share
Diluted EPS	$-5.90	$-3.68	$-10.31	$-10.15
Basic EPS	$-5.90	$-3.68	$-10.31	$-10.15
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-78,304,000	$-37,749,000	$-40,105,000	$-28,741,856
Reconciled Depreciation	$233,000	$588,000	$641,000	$762,995
EBITDA (Bullshit earnings)	$-78,304,000	$-37,749,000	$-40,105,000	$-34,072,450
EBIT	$-78,537,000	$-38,337,000	$-40,746,000	$-34,835,445
Diluted Average Shares	$13,317,116	$10,915,413	$4,327,568	$4,170,674
Basic Average Shares	$13,317,116	$10,915,413	$4,327,568	$4,170,674
Diluted NI Availto Com Stockholders	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Research And Development	$70,095,000	$32,222,000	$31,168,000	$16,136,826
Selling General And Administration	$15,215,000	$16,499,000	$13,910,000	$18,698,619
Other Gand A	$15,215,000	$16,499,000	$13,910,000	$18,698,619
Total Unusual Items	-	-	$8,519	$-5,330,594
Total Unusual Items Excluding Goodwill	-	-	$8,519	$-5,330,594
Gain On Sale Of Security	-	-	$8,519	$-330,594
Other Special Charges	-	-	-	$5,000,000

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$147,503,000	$142,428,000	$-6,905,000	$32,990,017
Total Assets	$168,195,000	$155,879,000	$28,272,000	$66,311,940
Total Non Current Assets	$1,241,000	$2,903,000	$4,726,000	$6,130,838
Current Assets	$166,954,000	$152,976,000	$23,546,000	$60,181,102
Other Current Assets	$3,015,000	$3,629,000	$2,448,000	$791,616
Restricted Cash	$670,000	$285,000	$192,000	$192,475
Cash Cash Equivalents And Short Term Investments	$163,269,000	$149,062,000	$20,906,000	$59,197,011
Cash And Cash Equivalents	$28,492,000	$17,198,000	$13,724,000	$17,002,715
Cash Equivalents	$27,141,000	$12,151,000	$9,695,000	$13,197,559
Cash Financial	$1,351,000	$5,047,000	$4,029,000	$3,805,156
Other Non Current Assets	-	$385,000	$690,000	$632,771
Prepaid Assets	-	-	-	-
Receivables	-	-	-	-
Debt
Total Debt	$1,633,000	$3,239,000	$20,885,000	$25,089,635
Long Term Debt And Capital Lease Obligation	$0	$1,633,000	$3,239,000	$20,659,780
Current Debt And Capital Lease Obligation	$1,633,000	$1,606,000	$17,646,000	$4,429,855
Net Debt	-	-	$2,485,000	$2,130,703
Current Debt	-	-	$16,209,000	$3,148,992
Other Current Borrowings	-	-	$15,908,000	$2,795,669
Long Term Debt	-	-	-	$15,984,426
Liabilities
Total Liabilities Net Minority Interest	$20,692,000	$13,451,000	$35,177,000	$33,321,923
Total Non Current Liabilities Net Minority Interest	$0	$1,633,000	$3,283,000	$20,681,985
Current Liabilities	$20,692,000	$11,818,000	$31,894,000	$12,639,938
Payables And Accrued Expenses	$16,200,000	$7,936,000	$14,209,000	$5,948,264
Payables	$2,215,000	$4,786,000	$3,179,000	$2,173,963
Accounts Payable	$2,215,000	$4,786,000	$3,179,000	$2,173,963
Current Notes Payable	-	$0	$301,000	$353,323
Interest Payable	-	$0	$1,342,098	$916,108
Other Non Current Liabilities	-	-	$44,000	$22,205
Other Current Liabilities	-	-	$39,000	$36,868
Equity
Common Stock Equity	$147,503,000	$142,428,000	$-6,905,000	$32,990,017
Total Equity Gross Minority Interest	$147,503,000	$142,428,000	$-6,905,000	$32,990,017
Stockholders Equity	$147,503,000	$142,428,000	$-6,905,000	$32,990,017
Gains Losses Not Affecting Retained Earnings	$-53,000	$35,000	$-1,000	$-126,092
Other Equity Adjustments	$-53,000	$35,000	$-1,000	$-126,092
Retained Earnings	$-555,430,000	$-476,893,000	$-436,684,000	$-392,080,667
Other
Ordinary Shares Number	$17,611,511	$12,179,482	$4,423,683	$4,171,296
Share Issued	$17,611,511	$12,179,482	$4,423,683	$4,171,296
Tangible Book Value	$147,503,000	$142,428,000	$-6,905,000	$32,990,017
Invested Capital	$147,503,000	$142,428,000	$9,304,000	$52,123,435
Working Capital	$146,262,000	$141,158,000	$-8,348,000	$47,541,164
Capital Lease Obligations	$1,633,000	$3,239,000	$4,676,000	$5,956,217
Total Capitalization	$147,503,000	$142,428,000	$-6,905,000	$48,974,443
Additional Paid In Capital	$702,984,000	$619,285,000	$429,780,000	$425,196,359
Capital Stock	$2,000	$1,000	$0	$417
Common Stock	$2,000	$1,000	$0	$417
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$0	$1,633,000	$3,239,000	$4,675,354
Current Capital Lease Obligation	$1,633,000	$1,606,000	$1,437,000	$1,280,863
Pensionand Other Post Retirement Benefit Plans Current	$2,859,000	$2,276,000	$2,325,488	$2,224,951
Current Accrued Expenses	$13,985,000	$3,150,000	$11,030,000	$3,774,301
Net PPE	$1,241,000	$2,518,000	$4,036,000	$5,498,067
Accumulated Depreciation	$-4,306,000	$-4,073,000	$-3,556,000	$-3,093,223
Gross PPE	$5,547,000	$6,591,000	$7,592,000	$8,591,290
Leases	$3,331,000	$3,331,000	$3,331,000	$3,330,855
Other Properties	$1,082,000	$2,133,000	$3,063,000	$3,884,252
Machinery Furniture Equipment	$1,134,000	$1,127,000	$1,198,000	$1,376,183
Properties	$0	$0	$0	$0
Other Short Term Investments	$134,777,000	$131,864,000	$7,182,000	$42,194,296

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-64,498,000	$-41,794,000	$-36,100,000	$-37,557,884
Operating Activities
Operating Cash Flow	$-64,491,000	$-41,794,000	$-36,100,000	$-37,544,435
Cash Flow From Continuing Operating Activities	$-64,491,000	$-41,794,000	$-36,100,000	$-37,544,435
Operating Gains Losses	-	-	$-20,435	$751,135
Investing Activities
Capital Expenditure	$-7,000	-	-	$-13,449
Investing Cash Flow	$-1,641,000	$-121,310,000	$35,642,000	$30,074,133
Cash Flow From Continuing Investing Activities	$-1,641,000	$-121,310,000	$35,642,000	$30,074,133
Financing Activities
Issuance Of Capital Stock	$77,426,000	$182,058,000	$53,000	$0
Financing Cash Flow	$77,426,000	$166,578,000	$-2,821,000	$-533,615
Cash Flow From Continuing Financing Activities	$77,426,000	$166,578,000	$-2,821,000	$-533,615
Net Common Stock Issuance	$77,426,000	$182,058,000	$53,000	$0
Common Stock Issuance	$77,426,000	$182,058,000	$53,000	$0
Net Other Financing Charges	-	-	$-190,902	-
Other
Repayment Of Debt	$0	$-15,480,000	$-3,247,000	$-2,367,594
Interest Paid Supplemental Data	$0	$2,818,000	$2,607,000	$1,969,583
End Cash Position	$29,162,000	$17,868,000	$14,394,000	$17,672,615
Beginning Cash Position	$17,868,000	$14,394,000	$17,673,000	$25,676,532
Changes In Cash	$11,294,000	$3,474,000	$-3,279,000	$-8,003,917
Net Issuance Payments Of Debt	$0	$-15,480,000	$-2,874,000	$-533,615
Net Long Term Debt Issuance	$0	$-15,480,000	$-2,874,000	$-119,000
Long Term Debt Payments	$0	$-15,480,000	$-3,247,000	$-1,500,729
Net Investment Purchase And Sale	$-1,634,000	$-121,310,000	$35,642,000	$30,079,482
Sale Of Investment	$161,457,000	$59,494,000	$69,527,000	$116,421,376
Purchase Of Investment	$-163,091,000	$-180,804,000	$-33,885,000	$-86,341,894
Net PPE Purchase And Sale	$-7,000	$0	$0	$-5,349
Purchase Of PPE	$-7,000	$0	$0	$-13,449
Change In Working Capital	$9,120,000	$-5,576,000	$4,094,000	$-3,298,652
Change In Other Current Liabilities	$-1,606,000	$-1,481,000	$-1,259,000	$-1,136,948
Change In Other Current Assets	$1,051,000	$1,142,000	$764,000	$615,897
Change In Payables And Accrued Expense	$9,041,000	$-4,008,000	$6,059,000	$-4,350,995
Change In Accrued Expense	$11,390,000	$-5,611,000	$5,031,000	$-4,094,160
Change In Payable	$-2,349,000	$1,603,000	$1,028,000	$-256,835
Change In Account Payable	$-2,349,000	$1,603,000	$1,028,000	$-256,835
Change In Prepaid Assets	$634,000	$-1,229,000	$-1,470,000	$1,573,394
Other Non Cash Items	$-229,000	$585,000	$805,000	$742,478
Stock Based Compensation	$6,288,000	$6,145,000	$3,470,000	$5,719,637
Amortization Of Securities	$-1,366,000	$-3,327,000	$-506,000	$124,875
Depreciation Amortization Depletion	$233,000	$588,000	$641,000	$762,995
Depreciation And Amortization	$233,000	$588,000	$641,000	$762,995
Depreciation	$233,000	$588,000	$641,000	$1,487,853
Net Income From Continuing Operations	$-78,537,000	$-40,209,000	$-44,604,000	$-42,346,903
Issuance Of Debt	-	$0	$373,000	$1,833,979
Long Term Debt Issuance	-	$0	$373,000	$1,381,729
Net Short Term Debt Issuance	-	-	$-52,660	$-414,615
Short Term Debt Payments	-	-	$-425,980	$-866,865
Short Term Debt Issuance	-	-	$373,320	$452,250
Sale Of PPE	-	-	$0	$8,100
Gain Loss On Investment Securities	-	-	$3,295	$81,380
Net Foreign Currency Exchange Gain Loss	-	-	$-23,730	$648,520
Gain Loss On Sale Of PPE	-	-	$0	$21,235
Change In Receivables	-	-	-	$0
Asset Impairment Charge	-	-	-	$0
Change In Other Working Capital	-	-	-	-

Fetched: 2026-06-18